CD55 was also significantly down regulated (P < 0.05) with approximately 3.8 fold in AML and ALL patients suggesting the possibility that cancer may evade complement attack mechanism and may even manipulate it to its benefit. The gene discussed is CD55; the disease is acute myeloid leukemia.